[1]韩艳,温利平,刘娜,等.补肾活血方对去卵巢大鼠骨代谢及骨密度的影响[J].中医正骨,2015,27(12):7-11.
　HAN Yan,WEN Liping,LIU Na,et al.Effect of Bushen Huoxue Fang(补肾活血方)on bone metabolism and bone mineral density in the ovariectomized rats[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(12):7-11.
点击复制

补肾活血方对去卵巢大鼠骨代谢及骨密度的影响()
分享到：

《中医正骨》[ISSN:1001-6015/CN:41-1162/R]

卷:
第27卷
期数:
2015年12期
页码:
7-11
栏目:
基础研究
出版日期:
2015-12-30

文章信息/Info

Title:
Effect of Bushen Huoxue Fang(补肾活血方)on bone metabolism and bone mineral density in the ovariectomized rats
作者:
韩艳1; 温利平2; 刘娜3; 陈霖1; 吴春雷1; 吴云刚1
1.温州医科大学附属第一医院,浙江 温州 325000;
2.温州医科大学附属第二医院,浙江 温州 325027;
3.陕西省西安市红会医院,陕西 西安 710054
Author(s):
HAN Yan1; WEN Liping2; LIU Na3; CHEN Lin1; WU Chunlei1; WU Yungang1
1.The First Affiliated Hospital of Wenzhou Medical University,Wenzhou 325000,Zhejiang,China
2.The Second Affiliated Hospital of Wenzhou Medical University,Wenzhou 325027,Zhejiang,China
3.The Red Cross Hospital of Xi'an City,Xi'an 710054,Shanxi,China
关键词:
骨质疏松; 绝经后;  补肾活血方;  骨密度;  骨代谢;  动物实验
Keywords:
osteoporosis; postmenopausal;  Bushen Huoxue Fang;  bone density;  bone metabolism;  animal experimentation
摘要:
目的:观察补肾活血方对去卵巢大鼠骨代谢和骨密度的影响。方法:将40只SD雌性大鼠随机分成假手术组、模型组、补肾活血方组和尼尔雌醇组,每组10只。假手术组行开腹术但不摘除卵巢,其他3组行双侧卵巢切除术。术后假手术组和模型组大鼠以蒸馏水灌胃(每次3 mL,每天1次),补肾活血方组大鼠以补肾活血方汤剂灌胃(每次15 g·kg-1,每天1次),尼尔雌醇组大鼠以研细的尼尔雌醇片和生理盐水配制成的混悬液灌胃(每次0.6 g·kg-1,每周1次)。灌胃12周后从大鼠心脏取血,离心后吸取上层血清,置入冰箱保存待检。处死大鼠后,切取右侧股骨中段做标本,同时取大鼠腰椎,置入冰箱保存待检。采用ELISA法测定血清Ⅰ型前胶原氨基端原肽(procollagen type Ⅰ N-terminal propeptide,PINP)、β-胶原降解产物(β isomer of C-terminal telopeptide of typeⅠcollagen,β-CTX)含量,并用双能X线骨密度测量仪检测腰椎骨密度。将冰冻切片做HE染色后,在显微镜下观察骨组织病理学改变。结果:①血清PINP、β-CTX含量。药物干预后各组大鼠血清PINP含量比较,差异有统计学意义(F=914.448,P=0.000)。组间两两比较,假手术组血清PINP含量低于模型组[(0.109±0.008)μg·mL-1,(0.252±0.006)μg·mL-1,q=-51.807,P=0.000]; 假手术组血清PINP含量与补肾活血方组[(0.163±0.006)μg·mL-1]、尼尔雌醇组[(0.169±0.005)μg·mL-1]比较,差异均无统计学意义[q=0.559,P=0.208; q=0.850,P=0.253]; 模型组血清PINP含量高于补肾活血方组和尼尔雌醇组(q=32.248,P=0.000; q=29.957,P=0.000); 补肾活血方组与尼尔雌醇组比较,差异无统计学意义(q=-0.290,P=0.317)。药物干预后各组大鼠血清β-CTX含量比较,差异有统计学意义(F=963.955,P=0.000)。组间两两比较,假手术组血清β-CTX含量低于模型组[(0.432±0.007)ng·mL-1,(0.766±0.005)ng·mL-1,q=-48.601,P=0.000]; 假手术组血清β-CTX含量与补肾活血方组[(0.482±0.006)ng·mL-1]、尼尔雌醇组[(0.494±0.008)ng·mL-1]比较,差异均无统计学意义(q=-0.172,P=0.215; q=0.980,P=0.322); 模型组血清β-CTX含量高于补肾活血方组和尼尔雌醇组(q=41.429,P=0.000; q=39.622,P=0.000); 补肾活血方组血清β-CTX含量与尼尔雌醇组比较,差异无统计学意义(q=-0.808,P=0.790)。②腰椎骨密度。药物干预后各组大鼠腰椎骨密度比较,差异有统计学意义(F=419.969,P=0.000)。组间两两比较,假手术组腰椎骨密度高于模型组[(0.170±0.004)g·cm-2,(0.097±0.005)g·cm-2,q=35.198,P=0.000]; 假手术组腰椎骨密度与补肾活血方组[(0.127±0.005)g·cm-2]、尼尔雌醇组[(0.126±0.004)g·cm-2]比较,差异均无统计学意义(q=2.444,P=0.157; q=1.167,P=0.230); 模型组腰椎骨密度低于补肾活血方组和尼尔雌醇组(q=-14.754,P=0.000; q=-14.031,P=0.000); 补肾活血方组腰椎骨密度与尼尔雌醇组比较,差异无统计学意义(q=0.723,P=0.474)。③骨组织形态。假手术组股骨骨小梁粗壮、饱满,壁厚,形态结构完整,排列紧密有序,呈网状,密度、面积正常,骨小梁间隙较小。模型组股骨骨小梁变细、变薄,有扭曲或断裂,骨小梁间隙增大。补肾活血方组和尼尔雌醇组股骨骨小梁较模型组明显增粗,排列尚整齐并连接成网,部分区域骨小梁间隙略增大。结论:补肾活血方能降低去卵巢大鼠血清PINP、β-CTX含量,提高骨密度,改善骨组织状况,但其具体作用机制尚不明确,有待进一步研究。
Abstract:
Objective:To observe the effect of Bushen Huoxue Fang(补肾活血方,BSHXF)on bone metabolism and bone mineral density(BMD)in the ovariectomized rats.Methods:Forty female SD rats were randomly divided into sham-operated group,model group,BSHXF group and nylestriol group,10 cases in each group.The rats in the sham-operated group underwent simple laparotomy while the others underwent bilateral ovariectomy.The rats in the sham-operated group and model group were intragastric administrated with distilled water(3ml at a time,once a day).The rats in BSHXF group were intragastric administrated with BSHXF decoction(15 g/kg at a time,once a day)and the rats in nylestriol group were intragastric administrated with the suspension of nylestriol tablets and normal saline(0.6 g/kg at a time,once a week).After 12-week intragastric administration,the blood samples were obtained from the heart of rats.The upper serum was sucked from the blood samples after centrifuging and was put into the refrigerator for further inspection.The rats were sacrificed and their right middle femurs were fetched out for making specimens and their lumbar vertebraes were fetched out and put into the refrigerator for further inspection.The serum content of procollagen type Ⅰ N-terminal propeptide(PINP)and β isomer of C-terminal telopeptide of typeⅠcollagen(β-CTX)were measured by using enzyme-linked immunosorbent assay(ELISA),and the BMD of lumbar spine were also detected by using dual-energy X-rays BMD radiomete.The pathological changes of bone tissues were observed under the microscope after the frozen sections were received HE staining.Results:There was statistical difference in the serum content of PINP between the 4 groups after the drug intervention(F=914.448,P=0.000).Further pairwise comparison showed that the serum content of PINP of sham-operated group was lower than that of model group(0.109+/-0.008 vs 0.252+/-0.006 μg/mL,q=-51.807,P=0.000).There was no statistical difference in the serum content of PINP between sham-operated group and BSHXF group(0.163+/-0.006 μg/mL)and between sham-operated group and nylestriol group(0.169+/-0.005 μg/mL)(q=0.559,P=0.208; q=0.850,P=0.253).The serum content of PINP was higher in model group compared to BSHXF group and nylestriol group(q=32.248,P=0.000; q=29.957,P=0.000).There was no statistical difference in the serum content of PINP between BSHXF group and nylestriol group(q=-0.290,P=0.317).There was statistical difference in the serum content of β-CTX between the 4 groups after the drug intervention(F=963.955,P=0.000).Further pairwise comparison showed that the serum content of β-CTX of sham-operated group was lower than that of model group(0.432+/-0.007 vs 0.766+/-0.005 ng/mL,q=-48.601,P=0.000).There was no statistical difference in the serum content of β-CTX between sham-operated group and BSHXF group(0.482+/-0.006 ng/mL)and between sham-operated group and nylestriol group(0.494+/-0.008 ng/mL)(q=-0.172,P=0.215; q=0.980,P=0.322).The serum content of β-CTX was higher in model group compared to BSHXF group and nylestriol group(q=41.429,P=0.000; q=39.622,P=0.000).There was no statistical difference in the serum content of β-CTX between BSHXF group and nylestriol group(q=-0.808,P=0.790).There was statistical difference in the BMD of lumbar spine between the 4 groups after the drug intervention(F=419.969,P=0.000).Further pairwise comparison showed that the BMD of lumbar spine of sham-operated group was higher than that of model group(0.170+/-0.004 vs 0.097+/-0.005 g/cm(2),q=35.198,P=0.000).There was no statistical difference in the BMD of lumbar spine between sham-operated group and BSHXF group(0.127+/-0.005 g/cm(2))and between sham-operated group and nylestriol group(0.126+/-0.004 g/cm(2))(q=2.444,P=0.157; q=1.167,P=0.230).The BMD of lumbar spine was lower in model group compared to BSHXF group and nylestriol group(q=-14.754,P=0.000; q=-14.031,P=0.000).There was no statistical difference in the BMD of lumbar spine between BSHXF group and nylestriol group(q=0.723,P=0.474).The femoral bone trabecula in the sham-operated group was thick and arranged tightly,and their morphological structure was complete and cancellous with normal density and area and small interspaces.The femoral bone trabecula in the model group was thin,and some of them were distorted or ruptured with enlarged interspace.The femoral bone trabecula in BSHXF group and nylestriol group were thicker than that of model group and arranged tightly and their trabecular interspace was slightly larger in some regions compared to model group.Conclusion:BSHXF can lower the serum content of PINP and β-CTX and increase the BMD and improve the status of bone tissue in the ovariectomized rats,while its specific mechanism is unclear and need to be further studied.

参考文献/References:

[1] 胡军,张华,牟青.骨质疏松症的流行病学趋势与防治进展[J].临床荟萃,2011,26(8):729-731.
[2] 李春雯.益气温经法对绝经后骨质疏松性髋部骨折患者骨转换指标的影响[J].中医正骨,2014,26(12):7-9.
[3] 李春雯,刘杰.杭州市骨质疏松性髋部骨折的初步调查[J].中医正骨,2013,25(12):42-44.
[4] 乔伟伟,赵先哲.骨质疏松动物模型研究进展和展望[J].实验动物与比铰医学,2011,31(1):73-78.
[5] 康轶鑫,李建川,李光磊.单味补肾药治疗骨质疏松症的研究进展(一)[J].国际中医中药杂志,2010,32(4):362-365.
[6] 林清,李劲平,栗会敏,等.补骨脂的研究进展[J].咸宁学院学报(医学版),2012,26(2):175-177.
[7] 陈春,张淑丽.红花等10种中药的雌激素活性研究分析[J].中国医药指南,2011,9(14):296-297.
[8] 夏庆华,路千里.熟地黄药理研究进展[J].江西中医学院学报,2008,20(6):96-97.
[9] Singer FR,Eyre DR.Using biochemical markers of bone turnover in clinical practice[J].Cleve Clin J Med,2008,75(10):739-750.
[10] 施鸣,范璐,陈新.骨代谢标志物与骨质疏松的相关性研究[J].标记免疫分析与临床,2012,19(6):351-353.
[11] 阙文君,冯正平.骨转换生化标志物的研究进展[J].中国骨质疏松杂志,2014,20(5):575-579.
[12] Mountzios G,Terpos E,Syrigos K,et al.Markers of bone remodeling and skeletal morbidity in patients with solid tumors metastatic to the skeleton receiving the biphosphonate zoledronic acid[J].Transl Res,2010,155(5):247-255.
[13] 俞华威,王兆杰,胡小军,等.抗骨质疏松药物应用的依据:骨生化代谢标志物及骨组织病理学[J].中国组织工程研究,2013,17(28):5126-5132.
[14] Naylor K,Eastell R.Bone turnover markers: use in osteoporosis[J].Nat Rev Rheumatol,2012,8(7):379-389.
[15] Biver E.Use of bone turnover markers in clinical practice[J].Curr Opin Endocrinol Diabetes Obes,2012,19(6):468-473.
[16] 张萌萌,毛未贤,马倩倩,等.骨代谢标志物在骨质疏松诊疗中的应用指南(2012年版)(日本骨质疏松症学会制定)[J].中国骨质疏松杂志,2013,19(7):645-657.
[17] Lee J,Vasikaran S.Current recommendations for laboratory testing and use of bone turnover markers in management of osteoporosis[J].Ann Lab Med,2012,32(2):105-112.

相似文献/References:

[1]李林军.应用膨胀式椎弓根螺钉内固定治疗合并骨质疏松的 胸腰椎退行性疾病[J].中医正骨,2015,27(08):49.
[2]李学朋,朱立国.骨疏康胶囊对去卵巢大鼠骨小梁的影响[J].中医正骨,2015,27(12):12.
　LI Xuepeng,ZHU Liguo.Effect of Gushukang Jiaonang(骨疏康胶囊)on bone trabecula in the ovariectomized rats[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(12):12.
[3]陈冠军,陈扬,庄汝杰.可灌注骨水泥椎弓根螺钉系统 在老年腰椎疾患手术中的应用[J].中医正骨,2015,27(02):40.
[4]王丹辉,贲越,韩梅.林蛙油治疗绝经后骨质疏松症的临床研究[J].中医正骨,2014,26(01):27.
　Wang Danhui*,Ben Yue,Han Mei..Clinical study of Rana temporaria oil in the treatment of postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2014,26(12):27.
[5]黄建华,黄建武,李慧辉,等.加味左归丸对绝经后骨质疏松症肝肾不足证 患者骨密度的影响[J].中医正骨,2013,25(11):19.
　Huang Jianhua*,Huang Jianwu,Li Huihui,et al.Effect of JIAWEI ZUOGUI pill on bone mineral density in postmenopausal osteoporosis patients with deficiency of liver and kidney[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2013,25(12):19.
[6]项旻,杨虹,林爱菊,等.绝经后2型糖尿病患者骨质疏松与血微量元素的关系研究[J].中医正骨,2013,25(12):20.
　Xiang Min*,Yang Hong,Lin Aiju,et al.Clinical study on the relationship between osteoporosis and serum trace elements levels in postmenopausal women with type 2 diabetes[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2013,25(12):20.
[7]史晓林,李春雯,张志强.弱阳离子磁珠分离技术和基质辅助激光解吸电离飞行时间质谱技术在原发性Ⅰ型骨质疏松症血清标志蛋白筛选中的应用[J].中医正骨,2014,26(03):5.
　Shi Xiaolin*,Li Chunwen,Zhang Zhiqiang..Application of magnetic beads based weak cation exchange separation technology and matrix-assisted laser desorption-ionization time of flight mass spectrometry technology in screening serum protein markers of primary type-Ⅰ osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2014,26(12):5.
[8]李明,徐明雄,冯左基,等.自拟壮骨方治疗绝经后骨质疏松症的疗效及作用机制研究[J].中医正骨,2014,26(09):21.
　Li Ming*,Xu Mingxiong,Feng Zuoji,et al.Study on the curative effect and mechanism of action of self-made ZHUANGGU decoction in treatment of postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2014,26(12):21.
[9]陈俊杰,李晴晴,夏瑢.脂代谢及血清内脂素水平与绝经后骨质疏松症的 相关性研究[J].中医正骨,2012,24(04):16.
　CHEN Jun-jie*,LI Qing-qing,XIA Rong.*.Study on the correlations between the levels of lipid metabolism and serum visfatin and postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2012,24(12):16.
[10]许超,肖鲁伟,吴承亮.绝经后女性骨质疏松症辨证分型与抑郁焦虑的关系研究[J].中医正骨,2011,23(12):3.
　XU Chao*,XIAO Lu-wei,WU Cheng-liang.*.Study on the relationship between the syndrome differ classification and the depression and anxiety for the postmenopausal women with osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2011,23(12):3.
[11]欧国峰,刘鑫,董博,等.绝经后骨质疏松症的免疫学研究进展[J].中医正骨,2016,28(08):70.
[12]施振宇,刘钟,陈文亮,等.中医综合疗法防治绝经后骨量减少的多中心临床研究[J].中医正骨,2017,29(04):1.
　SHI Zhenyu,LIU Zhong,CHEN Wenliang,et al.A multicenter clinical study of complex therapy of traditional Chinese medicine for prevention and treatment of postmenopausal osteopenia[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2017,29(12):1.
[13]梁文娜,李西海,李灿东.血清microRNA与绝经后骨质疏松症肾虚证的关系[J].中医正骨,2017,29(10):53.
[14]梁文娜,李西海,胡柳,等.二至丸抑制绝经后骨质疏松大鼠骨代谢紊乱的作用机制研究[J].中医正骨,2017,29(11):1.
　LIANG Wenna,LI Xihai,HU Liu,et al.Study on mechanism of action of Erzhi Wan(二至丸)in inhibiting bone metabolism disorder in rats with postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2017,29(12):1.
[15]刘晨,李兴勇,姚兴璋,等.绝经后骨质疏松症的流行病学概况及发病机制研究进展[J].中医正骨,2018,30(03):52.
[16]杨依然,刘钟,毛一凡,等.酪蛋白激酶-2相互作用蛋白1基于磷脂酰肌醇3-激酶/蛋白激酶B/哺乳动物雷帕霉素靶蛋白通路参与绝经后骨质疏松症发生发展过程中细胞自噬的机制[J].中医正骨,2018,30(04):59.
[17]曹俊青,郑剑南,张麟.右归丸联合阿仑膦酸钠口服治疗绝经后骨质疏松症肾阳虚证的临床研究[J].中医正骨,2018,30(05):20.
　CAO Junqing,ZHENG Jiannan,ZHANG Lin.A clinical study of oral application of Yougui Wan(右归丸)and alendronate sodium for treatment of postmenopausal osteoporosis with kidney-yang deficiency syndrome[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2018,30(12):20.
[18]李中万,徐绍俊,杨广钢,等.健肾方联合碳酸钙D3咀嚼片(Ⅱ) 治疗绝经后骨质疏松症肾阳虚证[J].中医正骨,2018,30(08):11.
　LI Zhongwan,XU Shaojun,YANG Guanggang,et al.Oral application of Jianshen Fang(健肾方)and calcium carbonate and Vitamin D3 chewable tablets(Ⅱ)for treatment of postmenopausal osteoporosis with kidney-yang deficiency syndrome[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2018,30(12):11.
[19]赵凡,刘全,吴连国.口服强骨饮联合碳酸钙D3片治疗绝经后骨质疏松症的临床研究[J].中医正骨,2019,31(04):26.
　ZHAO Fan,LIU Quan,WU Lianguo.Oral applications of Qianggu Yin(强骨饮)and calcium carbonate and Vitamin D3 tablets for treatment of postmenopausal osteoporosis:a clinical study[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2019,31(12):26.
[20]史晓林,杨依然,刘钟,等.基于蛋白质组学方法分析绝经后骨质疏松症全血差异蛋白[J].中医正骨,2019,31(06):7.
　SHI Xiaolin,YANG Yiran,LIU Zhong,et al.Analysis of proteins which are differentially expressed in whole blood of patients with postmenopausal osteoporosis using proteomics approach[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2019,31(12):7.

备注/Memo

备注/Memo:
2015-10-22收稿 2015-11-18修回
基金项目:浙江省温州市2014年第一期科技计划项目(Y20140013)
更新日期/Last Update: 2015-12-30